OIG contacts providers for CGM cost study
By HME News Staff
Updated 8:30 AM CDT, Tue April 30, 2024
WASHINGTON – The Office of Inspector General has begun sending emails and letters to a select group of continuous glucose monitor (CGM) suppliers as part of an evaluation for its study "Medicare Payments Compared to the Prices Available to Consumers and Suppliers for Continuous Glucose Monitors and Sensors," AAHomecare reports.
This study aims to determine the cost-effectiveness of Medicare payments in comparison to the supplier’s acquisition costs and other prices available to consumers.
“AAHomecare recommends suppliers diligently monitor their email and mail correspondence for any communication from the OIG,” the association stated in a bulletin. “It is imperative for suppliers who have received such requests to promptly respond within the specified timeframe to facilitate the OIG's analysis.”
When the OIG announced the study in its Work Plan in November 2023, it noted CMS allowed more than $1.1 billion in Medicare Part B payments for CGMs and sensors in 2022.
If the OIG identifies opportunities for Medicare to realize cost savings, CMS has the authority to either introduce CGMs into the competitive bidding program or exercise its authority of inherent reasonableness to adjust Medicare payments accordingly, according to AAHomecare.
Comments